Blood Markers of Early Pancreas Cancer

Patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) have only an 8% chance of
surviving 5 years after diagnosis. Most PDAC is advanced and not amenable to curative
therapies at the time of diagnosis, owing to lack of symptoms in early disease, nonspecific
symptoms when they do develop resulting in a delay in diagnosis. Identifying biomarkers of
early PDAC could facilitate screening for individuals at higher than average risk and
expedite the diagnosis in individuals with symptoms and substantially improve an individual's
chance of surviving the disease.

The investigators propose a longitudinal study of subjects at higher than average risk of
PDAC in order to generate clinical data and bank serial blood specimens. Subjects will
include individuals with family history of pancreas cancer, individuals with cystic pancreas
lesions or chronic pancreatitis, and individuals with new-onset diabetes. Identifying
specific biomarkers - blood markers and/or a clinical "prodrome" - in participants who go on
to develop PDAC could improve the diagnostic approach outcomes for patients diagnosed with
PDAC.

Inclusion Criteria:

General inclusion criteria:

1. Age ≥19

2. Able to provide written, informed consent

Exclusion Criteria:

General exclusion criteria:

1. Personal history of PDAC

2. Currently receiving treatment for a cancer diagnosis (excluding long-term hormonal
therapy)

3. Pre-diabetes on metformin for ≥ 3 years